🇺🇸 FDA
Pipeline program

CS-3150

CS3150-B-J204

Phase 2 small_molecule completed

Quick answer

CS-3150 for Diabetic Nephropathy is a Phase 2 program (small_molecule) at Daiichi Sankyo with 1 ClinicalTrials.gov record(s).

Program details

Company
Daiichi Sankyo
Indication
Diabetic Nephropathy
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials